Skip to content

canopusrecord engine body

field
frontiers
loop
body
docs

vela-science/vela

frontier

anti-amyloid-translation

evidence

vea_35b5a12f0cb3aec2

resultsread-only vieweressays

Search Canopus

Jump to a section, signal, campaign, document, primitive, work path, frontier, record index, atlas, constellation, agent, capability, or full-state search.

frontiers / frontier

Anti-amyloid translation in Alzheimer's disease

CC-BY-4.0vfr_5076e7b3ff8e6b0f

id: vfr_5076e7b3ff8e6b0f
license: CC-BY-4.0
findings: 144
accepted core: 44
contested: 9

144

findings

19

links

125

sources

147

evidence

9

contested

0.63

avg conf

recordoverview state sources proofenginereviewbodygraph

Evidence atom

back to sources

Merck patent on iminothiadiazine dioxide scaffold BACE inhibitors encompassing the verubecestat (MK-8931) compound class; covers C2-ring-substituted variants of the thiadiazinane core used in the EPOCH and APECS Phase 3 trials.

id: vea_35b5a12f0cb3aec2
frontier: Anti-amyloid translation in Alzheimer's disease
source: vs_5588c5efb07284af
finding: vf_a74a1efa53aa4ed8

evidence boundary

supports

observational

An evidence atom is an inspectable support unit. It is not a finding by itself; it supports or challenges a finding through review.

finding binding

therapeutic

Merck patent on iminothiadiazine dioxide scaffold BACE inhibitors encompassing the verubecestat (MK-8931) compound class; covers C2-ring-substituted variants of the thiadiazinane core used in the EPOCH and APECS Phase 3 trials.

inspect finding →

source binding

US9447085B2 — Iminothiadiazine dioxides containing a thioamide, amidine, or amide oxime group as BACE inhibitors, compositions, and their use (assignee: Merck Sharp and Dohme LLC) — Represents Merck's commercial IP position on the BACE1 inhibitor scaffold that dominated AD drug development 2012–2018; Phase 3 failure of verubecestat established that BACE inhibition at symptomatic stage is insufficient, reorienting the field toward earlier intervention and combination strategies.

vs_5588c5efb07284af

inspect source →

review context

unverified

2 events

2 reviewable changes and 0 evaluation records target this atom or its bound objects.

Evidence statement

Merck patent on iminothiadiazine dioxide scaffold BACE inhibitors encompassing the verubecestat (MK-8931) compound class; covers C2-ring-substituted variants of the thiadiazinane core used in the EPOCH and APECS Phase 3 trials.

locator

source:US9447085B2 — Iminothiadiazine dioxides containing a thioamide, amidine, or amide oxime group as BACE inhibitors, compositions, and their use (assignee: Merck Sharp and Dohme LLC) — Represents Merck's commercial IP position on the BACE1 inhibitor scaffold that dominated AD drug development 2012–2018; Phase 3 failure of verubecestat established that BACE inhibition at symptomatic stage is insufficient, reorienting the field toward earlier intervention and combination strategies.|section:curator_source

extraction method

manual_curation

support relation

supports

condition refs

vcnd_30b6fbe7f6e7401f

Caveats

No evidence-specific caveats are recorded.

Review, event, and evaluation records

4

events

vev_945fd8fbbaac1b39finding.reviewed
Accepted as a broad-frontier seed inside the anti-amyloid scope; source locator remains the authority.
reviewer:will-blair-bot · 2026-05-06
vev_df20b2cdc051c871finding.asserted
Manual finding added to frontier state
reviewer:will-blair-bot · 2026-05-06

reviewable changes

vpr_6f700e042277aa81finding.add
Manual finding added to frontier state
applied · reviewer:will-blair-bot · 2026-05-06
vpr_7029395b74841f83finding.review
Accepted as a broad-frontier seed inside the anti-amyloid scope; source locator remains the authority.
applied · reviewer:will-blair-bot · 2026-05-06

evaluations

No evaluation rows are attached.

vea_35b5a12f0cb3aec2 · evidence